Sylwia Fabiszewska

Bio: Sylwia Fabiszewska is an academic researcher. The author has contributed to research in topics: Vedolizumab & Inflammatory bowel disease. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.

Vedolizumab therapy in pediatric inflammatory bowel disease – case report

Abstract: Inflammatory bowel disease (IBD) is a term, which includes ulcerative colitis (UC) and Crohn’s disease (CD) – chronic inflammatory bowel diseases with unknown etiology. Disease is commonly thought to be caused by combination of immunological, genetic and environmental factors. Most often diagnosis of IBD is established among young, 15-29 years old people, but the age of diagnosis is systematically reduced. Treatment plan depends on phase of disease, symptoms intensity and patient age. The main type of treatment are enteral nutrition, pharmacological therapy and finally surgical intervention in case of insufficient response. Until now, in pediatric patients U.S. Food and Drug Administration (FDA) approved biologic agents, infliximab and adalimumab as CD treatment and infliximab only as UC treatment. Currently new biological agents are being studied as part of effective and safe IBD therapy in children. Particular attention is now given to vedolizumab which is already used and approved as part of IBD treatment algorithm in adults. Purpose of this article is to present two cases in which vedolizumab was used in CU as well as CD therapy in pediatric patients.

Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group

Abstract: AMA Fabiszewska S, Derda E, Szymańska E, Osiecki M, Kierkuś J. Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group. Pediatria Polska - Polish Journal of Paediatrics. 2023. doi:10.5114/polp.2023.128806. APA Fabiszewska, S., Derda, E., Szymańska, E., Osiecki, M., & Kierkuś, J. (2023). Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group. Pediatria Polska - Polish Journal of Paediatrics. https://doi.org/10.5114/polp.2023.128806 Chicago Fabiszewska, Sylwia, Edyta Derda, Edyta Szymańska, Marcin Osiecki, and Jarosław Kierkuś. 2023. "Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group". Pediatria Polska - Polish Journal of Paediatrics. doi:10.5114/polp.2023.128806. Harvard Fabiszewska, S., Derda, E., Szymańska, E., Osiecki, M., and Kierkuś, J. (2023). Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group. Pediatria Polska - Polish Journal of Paediatrics. https://doi.org/10.5114/polp.2023.128806 MLA Fabiszewska, Sylwia et al. "Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group." Pediatria Polska - Polish Journal of Paediatrics, 2023. doi:10.5114/polp.2023.128806. Vancouver Fabiszewska S, Derda E, Szymańska E, Osiecki M, Kierkuś J. Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group. Pediatria Polska - Polish Journal of Paediatrics. 2023. doi:10.5114/polp.2023.128806.

Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)

Abstract: The invention provides methods for treating pediatric inflammatory bowel disease patients using vedolizumab.